15,206 Shares in Simulations Plus, Inc. (NASDAQ:SLP) Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. bought a new position in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 15,206 shares of the technology company's stock, valued at approximately $424,000. Balyasny Asset Management L.P. owned 0.08% of Simulations Plus as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SLP. Jones Financial Companies Lllp increased its stake in shares of Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock valued at $34,000 after buying an additional 427 shares during the period. Johnson Financial Group Inc. bought a new stake in Simulations Plus in the fourth quarter valued at $39,000. Tower Research Capital LLC TRC increased its position in Simulations Plus by 42.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock valued at $72,000 after purchasing an additional 764 shares during the period. AlphaQuest LLC raised its stake in Simulations Plus by 502.9% in the fourth quarter. AlphaQuest LLC now owns 2,689 shares of the technology company's stock worth $75,000 after buying an additional 2,243 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Simulations Plus during the fourth quarter valued at approximately $86,000. 78.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the transaction, the director now owns 3,344,157 shares of the company's stock, valued at $112,062,701.07. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 19.40% of the company's stock.

Simulations Plus Stock Performance

Shares of SLP stock traded down $1.07 during mid-day trading on Wednesday, reaching $31.03. 151,236 shares of the company's stock traded hands, compared to its average volume of 212,751. The firm has a market capitalization of $623.94 million, a PE ratio of 77.56 and a beta of 1.10. Simulations Plus, Inc. has a 12 month low of $23.01 and a 12 month high of $50.98. The firm has a 50 day moving average price of $29.28 and a two-hundred day moving average price of $30.32.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. During the same quarter in the previous year, the company posted $0.20 earnings per share. Simulations Plus's revenue for the quarter was up 22.5% on a year-over-year basis. As a group, equities analysts expect that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SLP shares. KeyCorp boosted their target price on Simulations Plus from $32.00 to $40.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. StockNews.com raised shares of Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $50.00.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.